APA (7th ed.) Citation

Avallone, G., Bombelli, A., Gargiulo, L., Foti, C., Trave, I., Rossi, M., . . . Ortoncelli, M. (2025). Effectiveness, Safety, and Health-Related Quality of Life in Moderate-to-Severe Atopic Dermatitis Treated with Lebrikizumab: A 16-Week Nationwide Retrospective Cohort Study. Dermatology & Therapy, 15(12), 3671. https://doi.org/10.1007/s13555-025-01550-8

Chicago Style (17th ed.) Citation

Avallone, Gianluca, et al. "Effectiveness, Safety, and Health-Related Quality of Life in Moderate-to-Severe Atopic Dermatitis Treated with Lebrikizumab: A 16-Week Nationwide Retrospective Cohort Study." Dermatology & Therapy 15, no. 12 (2025): 3671. https://doi.org/10.1007/s13555-025-01550-8.

MLA (9th ed.) Citation

Avallone, Gianluca, et al. "Effectiveness, Safety, and Health-Related Quality of Life in Moderate-to-Severe Atopic Dermatitis Treated with Lebrikizumab: A 16-Week Nationwide Retrospective Cohort Study." Dermatology & Therapy, vol. 15, no. 12, 2025, p. 3671, https://doi.org/10.1007/s13555-025-01550-8.